ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases
Date of Original Version
ATP-phosphopeptide conjugates were synthesized and evaluated in vitro against c-Src and Lck. A number of Src SH2 domain inhibitors enhance the kinase catalytic activity by switching the closed inactive to the open active conformation. ATP-phosphopeptide conjugates were designed and synthesized as Src tyrosine kinase inhibitors based on a tetrapeptide sequence pTyr-Glu-Glu-Ile (pYEEI) and ATP to block the SH2 domain signaling and substrate phosphorylation by ATP, respectively. In general, ATP-phosphopeptide conjugates with optimal linkers such as compounds 5 and 7 (K i = 1.7-2.6 μM) showed higher binding affinities to the ATP-binding site relative to the other ATP-phosphopeptide conjugates having short or long linkers, 1-4 and 6, (K i = 10.1-16.1 μand ATP (K m = 74 μM). These ATP-phosphopeptide conjugates may serve as novel templates for designing protein tyrosine kinase inhibitors to block SH2 mediated protein-protein interactions and to counter the activation of enzyme that resulted from the SH2 inhibition. © 2004 Elsevier Ltd. All rights reserved.
Publication Title, e.g., Journal
Bioorganic and Medicinal Chemistry
Nam, Nguyen Hai, Sungsoo Lee, Guofeng Ye, Gongqin Sun, and Keykavous Parang. "ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases." Bioorganic and Medicinal Chemistry 12, 22 (2004). doi: 10.1016/j.bmc.2004.08.043.